MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...

– Deal potentially worth $200+ million increases Roche's investment in Freenome with $75 million equity instrument and R&D support through innovative applications and technology collaboration – ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min If Freenome manages to pass the ...

Exact Sciences announced on Wednesday that it acquired the rights to a blood-based colon cancer screening test from rival firm Freenome. Exact is paying Freenome $75 million for exclusive rights in ...

Gross margin was 69%, and adjusted gross margin was 72%. In addition, Exact Sciences shared initial results from an internal version of its colorectal cancer (CRC) blood test, showing sensitivities of ...

Freenome Holdings Inc. reported it is going public via a special purpose acquisition company. The company said it expects to raise $330 million, which it plans to use for the 2026 launch of its ...

– Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of real-world patient and ...